SCHEMBL69346

SCHEMBL69346

[c]1nocc1-c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.35
RAB9A P51151 3/20 0.34
NPC1 O15118 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MAPK1 P28482 2/20 0.33
TDO2 P48775 2/20 0.32
NOTUM Q6P988 3/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
CTRC Q99895 1/20 0.30
NR1H4 Q96RI1 1/20 0.30
LMNA P02545 1/20 0.30
TP53 P04637 1/20 0.30
HTT P42858 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
ATM Q13315 1/20 0.30
ALOX15 P16050 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8921348 0.78 ENPP3 (0.41) ALDH1A1RAB9ANPC1SMN1; SMN2NOTUM
SCHEMBL28031803 0.78 NPC1 (0.39) RAB9ANPC1SMN1; SMN2TDO2NOTUM
SCHEMBL1654513 0.78 NOTUM (0.39) ALDH1A1RAB9ANPC1SMN1; SMN2TDO2
SCHEMBL16060614 0.73 DYRK1A (0.47) ALDH1A1RAB9ANPC1SMN1; SMN2TDO2
SCHEMBL2821405 0.71 NOTUM (0.38) ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1
SCHEMBL69514 0.71 SMN1; SMN2 (0.40) ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1
SCHEMBL2182857 0.71 KDM4E (0.48) ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1
SCHEMBL2821209 0.71 ALDH1A1 (0.44) ALDH1A1RAB9ANPC1SMN1; SMN2MEN1
SCHEMBL4719301 0.69 ENPP3 (0.43) ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1
SCHEMBL8183045 0.68 ALDH1A1 (0.43) ALDH1A1RAB9ANPC1MAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374014-A1 CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-11-23 US claimed
EP-4153593-A1 CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2023-03-29 EP claimed
CN-114835736-A Compound, display panel and display device 武汉天马微电子有限公司 2022-08-02 CN claimed
WO-2021233852-A1 CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2021-11-25 WO claimed
CN-107531690-B 4,5,6, 7-tetrahydro-1H-pyrazolo [4,3-c ] pyridin-3-amine compounds as CBP and/or EP300 inhibitors 基因泰克公司 2020-11-06 CN claimed
EP-3224258-A1 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS Genentech, Inc. (US) 2017-10-04 EP claimed
WO-2016086200-A9 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH, INC. (US) 2016-06-23 WO claimed
WO-2016086200-A1 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH, INC. (US) 2016-06-02 WO claimed
CN-102686596-A Azabicyclo[2.2.1] heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands BRISTOL MYERS SQUIBB CO 2012-09-19 CN claimed
CN-102686595-A Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands BRISTOL MYERS SQUIBB CO 2012-09-19 CN claimed
US-6121300-A IN A TOPICAL COSMETIC AS SKIN ELASTICITY IMPROVER OR WRINKLE REDUCER; COMPOUNDS SUCH AS 3-(2-(3-PHENYL-5-ISOXAZOLYL)-2-OXOETHYL)-THIAZOLIUM; ADMINSISTERING TO TREAT CATARACTS, PROTEIN AGING AND DIABETES SYNVISTA THERAPEUTICS, INC. 2000-09-19 US claimed
WO-2000027395-A1 REVERSING ADVANCED GLYCOSYLATION CROSS-LINKS USING HETEROCYCLIC-SUBSTITUTED THIAZOLIUM SALTS ALTEON, INC. (US) 2000-05-18 WO claimed
EP-0784612-A1 UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-07-23 EP claimed
US-5547984-A FUNGICIDES ROHM AND HAAS COMPANY (US) 1996-08-20 US claimed
WO-1996010559-A1 UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-04-11 WO claimed
EP-0170498-B1 N-ACETONYL-SUBSTITUTED-AMIDES, COMPOSITIONS CONTAINING THEM AND THEIR USE IN COMBATING FUNGI ROHM AND HAAS COMPANY (US) 1991-09-11 EP claimed
US-4863940-A N-acetonyl-substituted amides and phytopathogenic fungicidal use thereof ROHM AND HAAS (US) 1989-09-05 US claimed
EP-0150433-B1 PROCESS FOR THE PREPARATION OF INSATURATED KETONES BASF Aktiengesellschaft (DE) 1986-12-30 EP claimed
EP-0170498-A2 N-acetonyl-substituted-amides, compositions containing them and their use in combating fungi ROHM AND HAAS COMPANY (US) 1986-02-05 EP claimed
EP-0150433-A2 Process for the preparation of insaturated ketones BASF Aktiengesellschaft (DE) 1985-08-07 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374014-A1 CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES CGAS, GLS2, GBA3 ALDH1A1 928/4885RAB9A 3343/4885NPC1 1805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.